Stomach cancer

New data show first-line triplet regimen of pembrolizumab, Herzuma® (biosimilar trastuzumab) and chemotherapy are effective in treatment of HER2-positive advanced gastric cancer

Friday, May 29, 2020 - 12:01am

Data presented today as part of the ASCO20 Virtual Scientific Program show that a first-line triplet regimen comprising of pembrolizumab, Herzuma (biosimilar trastuzumab) and chemotherapy is effective in patients with HER2-positive advanced gastric cancer (AGC).

Key Points: 
  • Data presented today as part of the ASCO20 Virtual Scientific Program show that a first-line triplet regimen comprising of pembrolizumab, Herzuma (biosimilar trastuzumab) and chemotherapy is effective in patients with HER2-positive advanced gastric cancer (AGC).
  • Gastric cancer is a leading cause of cancer-related deaths worldwide, with over a million new cases of gastric cancer diagnosed each year.
  • Clinical trials have evaluated trastuzumab in combination with chemotherapy as first-line treatment for metastatic (advanced) gastric cancer.
  • Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (Pembrolizumab, Trastuzumab, Chemotherapy) for HER2 positive advanced gastric cancer (AGC).

ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer

Friday, May 22, 2020 - 7:00am

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZenecas ENHERTU (fam-trastuzumab deruxtecan-nxki) has been granted Orphan Drug Designation (ODD) in the U.S. for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.

Key Points: 
  • Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZenecas ENHERTU (fam-trastuzumab deruxtecan-nxki) has been granted Orphan Drug Designation (ODD) in the U.S. for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.
  • No ILD-related deaths (grade 5) occurred in patients with gastric cancer in the phase 1 trial or in the DESTINY-Gastric01 trial.
  • ENHERTU also received SAKIGAKE designation in March 2018 from Japans Ministry of Health, Labour and Welfare (MHLW) for potential use in HER2 positive gastric cancer, and a supplemental New Drug Application was recently submitted to the Japan MHLW .
  • ENHERTU has not been approved in the EU, or countries outside of Japan and the United States, for any indication.

Eisai to Launch New Selbelle Premium Tablets and New Selbelle Premium Fine Granules

Monday, May 18, 2020 - 5:33am

Stomach ailments, such as indigestion unrelated to overeating and stomach discomfort, prevent the enjoyment of eating on a routine basis.

Key Points: 
  • Stomach ailments, such as indigestion unrelated to overeating and stomach discomfort, prevent the enjoyment of eating on a routine basis.
  • The compounding amount of 'teprenone' was increased to 150mg / day for New Selbelle Premium from 112.5 mg / day for the conventional product.
  • In addition, New Selbelle Premium contains two natural extracts that revitalize stomach functions and digestive enzymes that help to digest fat.
  • For more information about Eisai Co., Ltd., please visit https://www.eisai.com
    Media Inquiries: Public Relations Department Eisai Co., Ltd. +81-(0)3-3817-5120
    Copyright 2020 JCN Newswire .

Debbie's Dream Foundation: Curing Stomach Cancer Announces the Launch of New Dream Makers Miracle Fund for Patients and Their Families

Friday, May 8, 2020 - 1:32pm

PLANTATION,Fla., May 8, 2020 /PRNewswire/ --Debbie's Dream Foundation: Curing Stomach Cancer (DDF) is proud to announce the launch of its new Dream Makers Miracle Fund for stomach cancer patients and their families.

Key Points: 
  • PLANTATION,Fla., May 8, 2020 /PRNewswire/ --Debbie's Dream Foundation: Curing Stomach Cancer (DDF) is proud to announce the launch of its new Dream Makers Miracle Fund for stomach cancer patients and their families.
  • The initiative, which is part of DDF's Patient Resource Education Program, aims to spread joy within the stomach cancer community by providing patients and their families with bucket-list inspired experiences.
  • More information and updates about the Dream Makers Miracle Fund and its application process will be made available on DDF's website.
  • Debbie is considered a pioneer by many for bringing awareness to the plight of stomach cancer patients worldwide and the lack of federal funding for stomach cancer research.

Crestone, Inc. (Boulder, Colorado) Secures NIH Funding for Preclinical Development of Novel Antibiotic CRS3123 to Treat H. pylori Infections

Monday, April 27, 2020 - 1:00pm

CRS3123 is also entering a phase 2 clinical study for treatment of Clostridioides difficile infections under a separate NIH contract with Crestone.

Key Points: 
  • CRS3123 is also entering a phase 2 clinical study for treatment of Clostridioides difficile infections under a separate NIH contract with Crestone.
  • H. pylori is a bacterium known to be present in the stomachs of more than half the people in the world.
  • Complications associated with H. pylori infection occur in about 10% of people and include gastritis, ulcers or stomach cancer.
  • The WHO has classified H. pylori as a class I carcinogen and recently listed drug-resistant H. pylori as a priority pathogen.

Cannabics Pharmaceuticals Shows Specific Cultivars Identified to Have Positive Anti-Tumor Effects on Gastric Adenocarcinoma

Wednesday, March 11, 2020 - 12:40pm

Analysis of the scans revealed specific cultivars which have a more significant necrotic effect on Gastric Adenocarcinoma cells.

Key Points: 
  • Analysis of the scans revealed specific cultivars which have a more significant necrotic effect on Gastric Adenocarcinoma cells.
  • The results will be used to further breed the selected cultivars for specific cancers, focusing on Gastric cancers.
  • The cultivars to be developed will be the source for active pharmaceutical ingredients (API's) for future clinical studies.
  • For the latest updates on Cannabics Pharmaceuticals follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.

Gastric Cancer Drugs Industry Forecast to 2030 - Landscape Dominated by Eli Lilly & Company, Novartis, Merck, Otsuka Pharma, and Roche

Wednesday, March 4, 2020 - 10:45pm

Increase in number of cases in gastric cancer will drive the market for gastric cancer drugs.

Key Points: 
  • Increase in number of cases in gastric cancer will drive the market for gastric cancer drugs.
  • Stringent regulations and policies for approval of the drugs restrain the market for gastric cancer drugs.
  • Advances in the drugs for treatment of gastric cancer will have a positive influence on the gastric cancer drugs' market.
  • Global Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

Chi-Med Reports 2019 Full Year Results and Provides Updates on Key Clinical Programs

Tuesday, March 3, 2020 - 3:26pm

2019 was a year in which we laid the foundations for a new era for Chi-Med, said Simon To, Chairman of Chi-Med.

Key Points: 
  • 2019 was a year in which we laid the foundations for a new era for Chi-Med, said Simon To, Chairman of Chi-Med.
  • Set out below are some of Chi-Meds operating highlights for 2019 and so far this year.
  • As a result of our regulatory interaction with the NMPA12, we now expect to submit savolitinib NDA in early 2020.
  • Promising savolitinib efficacy in MET-amplified gastric cancer: The VIKTORY Phase II umbrella trial results were published in Cancer Discovery16.

Debbie's Dream Foundation: Curing Stomach Cancer Will Highlight Advocacy Milestones at the 11th Annual Dream Makers Gala

Thursday, February 20, 2020 - 1:38pm

FORT LAUDERDALE, Fla., Feb. 20, 2020 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) will host its 11th annual Dream Makers Gala on Saturday, April 18, 2020, at Margaritaville Hollywood Beach Resort in Hollywood, Florida.

Key Points: 
  • FORT LAUDERDALE, Fla., Feb. 20, 2020 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) will host its 11th annual Dream Makers Gala on Saturday, April 18, 2020, at Margaritaville Hollywood Beach Resort in Hollywood, Florida.
  • "I am so honored to be part of Debbie's Dream Foundation and our 2020 Gala Committee," said Gala Chair Katie Ingram.
  • DDF will also award research grants to help support efforts towards finding a cure for stomach cancer.
  • Debbie is considered a pioneer by many for bringing awareness to the plight of stomach cancer patients worldwide and the lack of federal funding for stomach cancer research.

Debbie's Dream Foundation: Curing Stomach Cancer Announces 2019 Scholarship Essay Contest Winners

Thursday, January 30, 2020 - 1:33pm

FORT LAUDERDALE, Fla., Jan. 30, 2020 /PRNewswire/ --Debbie's Dream Foundation: Curing Stomach Cancer (DDF) is proud to announce the winners of the 2019 DDF Scholarship Essay Contest.

Key Points: 
  • FORT LAUDERDALE, Fla., Jan. 30, 2020 /PRNewswire/ --Debbie's Dream Foundation: Curing Stomach Cancer (DDF) is proud to announce the winners of the 2019 DDF Scholarship Essay Contest.
  • Nasir Thompson, 10, from Las Vegas won $100 in the elementary school division for his essay on ways to treat stomach cancer and his dreams for finding a cure.
  • Each category had a different essay prompt which asked questions regarding dreams, thoughts, and financial resources for curing stomach cancer.
  • Debbie is considered a pioneer by many for bringing awareness to the plight of stomach cancer patients worldwide, as well as to the lack of federal funding for stomach cancer research.